Results 21 to 30 of about 70,747 (277)

Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™). [PDF]

Neurol Ther, 2015
Ziemssen T, Sylvester L, Rametta M, Ross AP.   +3 more
europepmc   +3 more sources

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. [PDF]

Clin Drug Investig, 2019
Xu Y, Mao N, Chirikov V, Du F, Yeh YC, Liu L, Liu R, Gao X.   +7 more
europepmc   +3 more sources

Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis. [PDF]

Adv Ther, 2014
Marziniak M, Meuth S.
europepmc   +3 more sources

Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis

EClinicalMedicine, 2021
Background: The timing of administration of agents and use of combination treatments in COVID-19 remain unclear. We assessed the effectiveness of therapeutics in cohorts in Hong Kong SAR and Anhui, China.
Carlos K.H. Wong, Eric Y.F. Wan, Sihui Luo, Yu Ding, Eric H.Y. Lau, Ping Ling, Xiaowen Hu, Edward C.H. Lau, Jerry Wong, Xueying Zheng, Benjamin J. Cowling, Jianping Weng, Gabriel M. Leung   +12 more
doaj   +1 more source

Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study. [PDF]

BMC Neurol, 2018
Kotterba S, Neusser T, Norenberg C, Bussfeld P, Glaser T, Dörner M, Schürks M.   +6 more
europepmc   +3 more sources

Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients [PDF]

Arquivos de Neuro-Psiquiatria, 2006
Since 1993 the Federal Drug Administration approved the use of immunomodulatory therapy in multiple sclerosis (MS), modifying the natural course of disease, as demonstrate our experience in treatment of MS patients at the MS Treatment Center (CATEM ...
Charles Peter Tilbery, Maria Fernanda Mendes, Bianca Etelvina Santos de Oliveira, Rodrigo Barbosa Thomaz, Giorge Ribeiro Kelian   +4 more
doaj   +1 more source

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. [PDF]

J Neurol Neurosurg Psychiatry, 2014
Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D, BENEFIT Study Group.   +14 more
europepmc   +3 more sources

Nowe perspektywy leczenia wtórnie postępującej postaci stwardnienia rozsianego

Aktualności Neurologiczne, 2015
Stwardnienie rozsiane jest przewlekłą autoimmunologiczną chorobą ośrodkowego układu nerwowego o nieznanej przyczynie i zmiennym przebiegu. W około 85% przypadków najpierw występuje postać rzutowo-remisyjna, która po pewnym czasie (różniącym się w ...
Magdalena Noga, Halina Bartosik-Psujek
doaj   +1 more source

Erupção acneiforme aguda induzida por interferon beta-1b durante tratamento para esclerose múltipla Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis

Anais Brasileiros de Dermatologia, 2011
Esclerose múltipla é uma doença inflamatória desmielinizante, com presumida origem autoimune, que afeta o sistema nervoso central. A principal modalidade terapêutica é baseada no uso de imunomoduladores, como o interferon beta, que são geralmente bem ...
Dário Júnior de Freitas Rosa, Fernanda de Abreu Toledo Matias, Sâmya Diégues Cedrim, Ronaldo Figueiredo Machado, Alessandra Almeida Montenegro de Sá, Vânia Carolina Piccinini Silva   +5 more
doaj   +1 more source

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.

PLoS ONE, 2022
BackgroundSiponimod is an effective treatment for patients with secondary progressive multiple sclerosis (SPMS), with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, however there is a ...
Paolo Angelo Cortesi, Ippazio Cosimo Antonazzo, Claudio Gasperini, Mihaela Nica, Daniela Ritrovato, Lorenzo Giovanni Mantovani   +5 more
doaj   +2 more sources